Pharmaceutical compositions

The present invention provides liquid compositions comprising albiglutide or a variant thereof, a buffering agent, at least one saccharide and/or at least one polyol, at least one stabilizing agent and optionally a surfactant wherein said albiglutide remains stable in said liquid composition. Albiglutide or a variant thereof can be considered to remain stable in liquid if at least about >=96% of said albiglutide or a variant thereof remains as a monomer in the liquid composition over a period of at least one week. 本发明提供了液体组合物，其包含阿必鲁肽或其变体、缓冲剂、至少种糖和/或至少种多元醇、至少种稳定剂和任选的表面活性剂，其中所述阿必鲁肽在所述液体组合物中保持稳定。如果至少约≥96％的所述阿必鲁肽或其变体在至少周的时间内在液体组合物中保留为单体，则可认为阿必鲁肽或其变体在液体中保持稳定。